Human Genome Sciences, Inc. v. Kappos

CourtDistrict Court, District of Columbia
DecidedSeptember 23, 2010
DocketCivil Action No. 2010-0575
StatusPublished

This text of Human Genome Sciences, Inc. v. Kappos (Human Genome Sciences, Inc. v. Kappos) is published on Counsel Stack Legal Research, covering District Court, District of Columbia primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Human Genome Sciences, Inc. v. Kappos, (D.D.C. 2010).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF COLUMBIA

____________________________________ ) HUMAN GENOME SCIENCES, INC., ) ) Plaintiff, ) ) v. ) Civil Action No. 10-0575 (ESH) ) HON. DAVID J. KAPPOS, ) Under Secretary of Commerce for ) Intellectual Property & Director of the ) United States Patent & Trademark ) Office, ) ) Defendant. ) ____________________________________)

MEMORANDUM OPINION

Plaintiff Human Genome Sciences seeks to have the patent term adjustments (PTAs) for

four of its patents recalculated due to alleged miscalculations by the United States Patent and

Trademark Office (“USPTO”). Plaintiff’s original complaint sought recalculation for two of its

patents, and its Amended Complaint added similar claims for two other patents. Defendant

moved to strike the Amended Complaint on grounds that it was in fact a supplemental pleading

that could not, under Fed. R. Civ. P. 15(d), be filed without the Court’s permission, which

plaintiff had not obtained. Defendant also moved to remand the PTA claims in the original

complaint to the USPTO for partial recalculation.

As explained herein, the Court finds that plaintiff’s Amended Complaint is indeed an

amendment and not a supplemental pleading and therefore denies defendant’s motion to strike.

The Court grants defendant’s motion to remand with the understanding that the Court will retain

jurisdiction over the matter. BACKGROUND

Under 35 U.S.C. § 154(b)(1), a patent’s term may be extended if the USPTO causes

certain delays in the prosecution process (“USPTO delay”) or if the patent takes longer than

three years to issue (“3-year maximum pendency delay”). A patent’s term is reduced for

prosecution delays caused by the applicant (“applicant delay”). Id. § 154(b)(2). The USPTO’s

longstanding method of calculating PTA was rejected by the Federal Circuit in Wyeth v. Kappos,

591 F.3d 1364 (Fed. Cir. 2010), in favor of a method more generous to patent holders.1

Plaintiff is the assignee of United States Patent Nos. 7,601,351 (“the ’351 patent”),

7,605,236 (“the ’236 patent”), 7,064,189 (“the ’189 patent”), and 7,138,501 (“the ’501 patent”).

(First Am. Compl. ¶ 1.) Patents ’351 and ’236 were issued in October 2009. (Compl. ¶¶ 36, 41).

On April 9, 2010, plaintiff sued to have their PTAs recalculated to comply with Wyeth and also

to correct the USPTO’s allegedly erroneous measurement of prosecution delays. (See Compl. ¶¶

61-76.) Plaintiff’s suit was timely under § 154(b)(4)(A), which provides that civil actions

challenging PTA determinations must be brought “within 180 days after the grant of the patent.”

On July 20, 2010, plaintiff amended its complaint to seek similar recalculations for

patents ’189 and ’501. (First. Am. Compl. ¶¶ 100-131.) These patents were issued and their

PTAs determined in 2006.2 (First Am. Compl. ¶¶ 76, 79, 91-92.) Plaintiff alleges that these

PTA claims are timely because the 180-day limitations period is either inapplicable or should be

tolled under the doctrine of equitable tolling or under the discovery rule. (Id. ¶¶ 137, 144-

1 The USPTO had interpreted § 154(b) such that whenever a patent application was subject to both USPTO delay and 3-year maximum pendency delay, the delays overlapped and the applicant could only be awarded PTA for one of the two delays, whichever was longer. The Federal Circuit rejected this reading, holding instead that the two types of delays could only overlap if they occurred on the same calendar dates. Wyeth, 591 F.3d at 1369-70. 2 Patent ’189 was issued and its PTA determined in June 2006; patent ’501 was issued and its PTA determined in November 2006. (First Am. Compl. ¶¶ 76, 79, 91-92.) 2 45,151-52.) On March 5, 2010, prior to filing its original complaint, plaintiff had petitioned

defendant to reconsider these patents’ PTAs in light of Wyeth. (Id. ¶¶ 77, 97.) However,

defendant dismissed plaintiff’s ’189 petition on April 21, 2010 and to date has made no decision

regarding the ’501 petition. (Id.)

Defendant moves to strike the Amended Complaint on grounds that it is not an

amendment under Fed. R. Civ. P 15(a), but rather a supplemental pleading under Rule 15(d), for

which plaintiff was required to obtain leave of court. (Def.’s Mot. to Strike Am. Compl. at 1.)

Plaintiff opposes defendant’s motion or, in the alternative, seeks leave to file the pleading nunc

pro tunc. (Id. at 5.)

Defendant also moves to remand plaintiff’s ’351 and ’236 claims to the USPTO for

recalculation of the patents’ PTAs in light of Wyeth and for reconsideration of plaintiff’s

applicant delay claims. (Def.’s Mot. to Remand at 1.) Plaintiff consents to a remand only if all

of its claims relating to all four patents are remanded and the Court retains jurisdiction over the

action. (Pl.’s Conditional Opp’n. to Def.’s Mot. to Remand at 2.)

ANALYSIS

I. AMENDED COMPLAINT

The parties disagree as to whether plaintiff’s Amended Complaint is in fact an

amendment under Fed. R. Civ. P. 15(a) or a supplemental pleading under Fed. R. Civ. P. 15(d).

The significance of this distinction lies in the fact that while the rules permit amendments

without leave of court under certain circumstances, supplements always require leave of court.

Fed. R. Civ. P. 15(a)(1), (d).

Unlike amendments, which “typically rest on matters in place prior to the filing of the

original pleading,” U.S. v. Hicks, 283 F.3d 380, 385 (D.C. Cir. 2002), supplements set out

“transaction[s], occurrence[s], or event[s] that happened after the date of the pleading to be 3 supplemented.” Fed. R. Civ. P. 15(d). However, a pleading generally does not become a

supplement merely because it references facts that occurred subsequent to the original complaint.

Rather, “the appropriate bases for supplemental pleadings are new facts bearing on the

relationship between the parties.” Hicks, 283 F.3d at 386 (emphasis added). Thus, supplemental

pleadings are used, e.g., “to set forth new facts that update the original pleading or provide the

basis for additional relief; to put forward new claims or defenses based on events that took place

after the original complaint or answer was filed; [and] to include new parties where subsequent

events have made it necessary to do so.” Id. (citing 6A Charles Alan Wright et al., Federal

Practice and Procedure § 1504 (3d ed. 2010)).

Here, plaintiff’s new claims are based on events that occurred before the original

complaint was filed. The Amended Complaint seeks PTA recalculations for patents ’189 and

’501 in light of Wyeth. Prior to the filing of the original complaint, both patents were issued and

their PTAs calculated, Wyeth was decided, and plaintiff sought relief directly from the USPTO.

(Pl.’s Opp’n. to Def.’s Mot. to Strike Am. Compl. at 2-3.)

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Hicks, Eric A.
283 F.3d 380 (D.C. Circuit, 2002)
Hall v. Central Intelligence Agency
437 F.3d 94 (D.C. Circuit, 2006)
Wyeth v. Kappos
591 F.3d 1364 (Federal Circuit, 2010)
Montgomery Environmental Coalition v. Fri
366 F. Supp. 261 (District of Columbia, 1973)

Cite This Page — Counsel Stack

Bluebook (online)
Human Genome Sciences, Inc. v. Kappos, Counsel Stack Legal Research, https://law.counselstack.com/opinion/human-genome-sciences-inc-v-kappos-dcd-2010.